Author:
Favas Catarina,Isenberg David A.
Publisher
Springer Science and Business Media LLC
Reference30 articles.
1. Rahman, A. & Isenberg, D. A. Systemic lupus erythematosus. N. Engl. J. Med. 358, 929–939 (2008).
2. Hostmann, A., Jacobi, A. M., Mei, H., Hiepe, F. & Dorner, T. Peripheral B cell abnormalities and disease activity in systemic lupus erythematosus. Lupus 17, 1064–1069 (2008).
3. Reff, M. E. et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83, 435–445 (1994).
4. Merrill, J. T. et al. Efficacy and safety of rituximab in patients with moderately to severely active systemic lupus erythematosus (SLE): results from the randomized, double-blind phase II/III study EXPLORER (abstract 12). Presented at the American College of Rheumatology Annual Meeting, 2008 October, San Francisco, CA, USA.
5. Li, E. K. et al. Is combination rituximab with cyclophosphamide better than rituximab alone in the treatment of lupus nephritis? Rheumatology (Oxford) 48, 892–898 (2009).
Cited by
60 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献